目的 探討翁瀝通膠囊聯(lián)合坦索羅辛治療前列腺增生癥的臨床療效。方法 選取2019年4月—2020年4月南陽市腫瘤醫(yī)院收治的82例前列腺增生癥患者為研究對象，隨機分為對照組和治療組（每組各41例）。對照組口服鹽酸坦索羅辛緩釋膠囊，0.2 mg/次，1次/d；治療組在對照組基礎上口服翁瀝通膠囊，1.2 g/次，2次/d。兩組均連續(xù)治療12周。比較兩組的臨床療效，觀察兩組相關量表評分、彩超多普勒超聲指標、血清學因子的變化情況。結(jié)果 治療后，治療組總有效率是97.56%，顯著高于對照組的82.93%（P<0.05）。經(jīng)治療，兩組國際前列腺癥狀（IPSS）評分、中醫(yī)癥候評分均較治療前顯著降低，但國際勃起功能（ⅡEF-5）評分、生活質(zhì)量（QOL）評分均顯著升高（P<0.05）；治療后，治療組IPSS評分、中醫(yī)癥候評分低于對照組，而ⅡEF-5評分、QOL評分高于對照組（P<0.05）。經(jīng)治療，兩組前列腺體積（PV）、殘余尿量（PVR）均顯著降低，而最大尿流率（Q_max）、顯著升高（P<0.05）；治療后，治療組PV、PVR顯著低于對照組，而Q_max高于對照組（P<0.05）。經(jīng)治療，兩組血清缺氧誘導因子-1α（HIF-1α）、結(jié)締組織生長因子（CTGF）、細胞凋亡抑制因子-2（Bcl-2）、胰島樣細胞生長因子-1（IGF-1）均較治療前顯著降低，但轉(zhuǎn)化生長因子β1（TGF-β1）顯著升高（P<0.05）；治療后，治療組HIF-1α、CTGF、Bcl-2、IGF-1低于對照組，而TGF-β1高于對照組（P<0.05）。結(jié)論 翁瀝通膠囊聯(lián)合坦索羅辛治療前列腺增生癥可有效改善患者下尿路癥狀，改善機體HIF-1α、CTGF、Bcl-2、TGF-β1、IGF-1水平，有利于提高患者生活質(zhì)量和改善患者殘余尿量及縮小前列腺體積，有著良好臨床應用價值。

Objective To investigate the clinical efficacy of Wenglitong Capsules combined with tansulosin hydrochloride in treatment of benign prostatic hyperplasia. Methods A total of 82 patients with benign prostatic hyperplasia who were treated in Nanyang Cancer Hospital from April 2019 to April 2020 were selected as the research subjects and randomly divided into control group and treatment group (41 cases in each group). Patients in the control group were po administered with Tamsulosin Hydrochloride Sustained Release Capsules, 0.2 mg/time, once daily. Patients in the treatment group were po administered with Wenglitong Capsules on the basis of the control group, 1.2 g/time, twice daily. Patients in two groups were treated for 12 weeks. After treatment, the clinical efficacy was evaluated, and the changes of related scale scores, color Doppler ultrasonography and serological factors were observed in the two groups. Results After treatment, the total effective rate of the treatment group was 97.56%, which was significantly higher than that of the control group (82.93%, P<0.05). After treatment, international prostate symptom (IPSS) score and TCM symptom score were significantly decreased in both groups, but international erectile function (ⅡEF-5) score and quality of life (QOL) score were significantly increased (P<0.05). After treatment, IPSS score and TCM syndrome score in the treatment group were lower than those in the control group, while ⅡEF-5 score and QOL score were higher than those in the control group (P<0.05). After treatment, PV and PVR in both groups were significantly decreased, while Q_max was significantly increased (P<0.05). After treatment, PV and PVR in the treatment group were significantly lower than those in the control group, while Q_max in the treatment group was higher than those in the control group (P<0.05). After treatment, serum hypoxia inducible factor-1α (HIF-1α), connective tissue growth factor (CTGF), apoptosis inhibitor factor-2 (Bcl-2) and islet like cell growth factor-1 (IGF-1) were significantly decreased, but transforming growth factorβ1 (TGF-β1) was significantly increased in both groups (P < 0.05). After treatment, HIF-1α, CTGF, Bcl-2 and IGF-1 in treatment group were lower than those in control group, while TGF-β1 was higher than those in control group (P<0.05). Conclusion Wenglitong Capsules combined with tansulosin hydrochloride can effectively improve the symptoms of patients with lower urinary tract in treatment of benign prostatic hyperplasia, also can improve the levels of HIF-1α, CTGF, Bcl-2, TGF-β1 and IGF-1, which is conducive to improve the life quality of patients, improve the residual urine volume and reduce the size of the prostate, and which has good clinical application value.

R983